Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

2018167 citationsJournal Articlehybrid Open Access

Authors

Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.

Good health and well-being

Published in: Annals of the Rheumatic Diseases

Volume 78, Issue 3, pp. 413-420

Field-Weighted Citation Impact: 12.95